Provided herein multifunctional compounds that bind and modify nucleic acids, forming crosslinks between the nucleic acid strands. In particular embodiments, the multifunctional nucleic-acid binding/modifying compounds are selective for nucleic acids of non-viable cells and viruses (i.e., they are excluded from or degraded within viable cells and viruses), and therefore find use in methods for detecting or discriminating viable and non-viable cells/viruses and nucleic acids therefrom.

Provided herein multifunctional compounds that bind and modify nucleic acids, forming crosslinks between the nucleic acid strands. In particular embodiments, the multifunctional nucleic-acid binding/modifying compounds are selective for nucleic acids of non-viable cells and viruses (i.e., they are excluded from or degraded within viable cells and viruses), and therefore find use in methods for detecting or discriminating viable and non-viable cells/viruses and nucleic acids therefrom.

Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.

Described herein is the development of synthetic routes to produce a wide variety of substituted phenanthridines, specifically, multidentate phenanthridine-containing ligand frameworks capable of anchoring to Pt via more than one binding site and with the phenanthridinyl moiety co-planar to the coordination plane of Pt. The multidentate chelation is designed to attenuate the reactivity of the platinum complex in vivo, and ultimately help mitigate side effects. In addition, the geometry of phenanthridine binding to the metal centre is altered compared to in phenanthriplatin, thanks to the constraints of the ligand geometry. By enforcing coplanar binding with the metal's square planar coordination plane, these compounds exhibit altered modes of activity, and should hence enhance/change the spectrum of activity of our prodrug candidates compared with phenanthriplatin.

The present invention relates to compounds of the formula (1) and mixture comprising these compounds, which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds and mixtures.

The present invention relates to compounds of the formula (1) and mixture comprising these compounds, which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds and mixtures.

The present disclosure includes compounds, compositions, and methods for nucleic acid amplification reactions. In particular, the present disclosure provides compounds, compositions, and methods for viability PCR (vPCR) applications, in which the compounds that selectively bind to nucleic acids from non-viable cells.

The present disclosure includes compounds, compositions, and methods for nucleic acid amplification reactions. In particular, the present disclosure provides compounds, compositions, and methods for viability PCR (vPCR) applications, in which the compounds that selectively bind to nucleic acids from non-viable cells.

The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.